Lead Compound

Type: Keyphrase
Name: Lead Compound
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Molecular Templates Presents Preclinical Data on Engineered Toxin Bodies (ETBs) at the AACR Annual Meeting

Presentations included a report on the development of CD20 and CD38targeting lead therapeutics discovered using its novel biologic platformMolecular Templates, Inc., a biopharmaceutical company focused on thediscovery and development of a new class of ... [Published 4 Traders - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Arno Therapeutics annual net loss up

Arno Therapeutics, Inc., a biopharmaceutical company, has reported that net loss for the year ended December 31, 2013 was $39.66 million, or $5.28 loss per share, compared to a net loss of $14.39 million, or $3.17 loss per share, for the year ended December ... [Published Individual.com - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Data on Hepatitis C Virus Discussed by Researchers at Merck Research Labs

(NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Current study results on Liver Diseases and Conditions have been published. According to news reporting originating in Kenilworth, New Jersey, by NewsRx journalists, research stated, ... [Published NewsRX - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 2 reports

Nora Therapeutics Announces $18 Million Series B Financing

PALO ALTO, Calif.The Series B financing was led by Novo A/S and included participation from all Series A investors – Burrill & Company, Prospect Venture Partners, Rho Ventures, and Vivo Capital. In connection with the financing, Heath Lukatch"The significant ... [Published PR Newswire - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD

PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF (vascular ... ... [Published Big News Network - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Medac Pharma gets FDA approval for trade name Rasuvo for injectable MTX product

US-based pharmaceutical firm Medac Pharma has received approval from the US Food and Drug Administration (FDA) for the name Rasuvo for its lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen.Rasuvo, ... [Published Pharmaceutical Business Review - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Albireo Lead Compound A4250 Shows Promise Against Liver Injury In Mice

By Estel Grace MasangkaySwedish biotechnology company Albireo announced that its lead compound A4250 for cholestatic liver disease was successful in protecting against bile acid-mediated cholestatic liver damage in mice.A4250 belongs to the ileal bile ... [Published Bioresearch Online - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

Albireo’s Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile ...

Albireo (http://www.albireopharma.com) today announced that inhibition of ileal bile acid transport by A4250 (http://www.albireopharma.com/Content.aspx?PageID=769869&PageTypeID=3), the company’s lead compound for cholestatic liver diseases, protects against ... [Published b3c Newswire - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro

MONTREAL, QC -- (Marketwired) -- 04/07/14 -- Sunshine Biopharma Inc"Isomeric forms of a compound refer to the fact that the compound has different arrangements of its atoms in space," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. ... [Published BusinessWeek - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 5 reports

Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014

Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2 ... [Published Noodls - Apr 04 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Former winners of innovation awards: where are they now?

2010: Sigmoid PharmaInaugural winner with a gut feeling for drug deliveryThere’s no such thing as an overnight success in the world of biopharmaceutical development.But for Irish company Sigmoid Pharma , several years of researching, developing and testing ... [Published Irish Times - Mar 31 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

Efficient Hit and Lead Compound Evaluation Strategy Based on Off-Rate Screening by Surface Plasmon Resonance

Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, United States ... [Published Journal of Medicinal Chemistry - Mar 22 2014]

Quotes

...88 million, as compared to $11.15 million as of December 31, 2012. Glenn Mattes, president and CEO of Arno Therapeutics, said: "2013 was a pivotal year at Arno, and our accomplishments during the past year give us confidence that 2014 will achieve further clinical advancement and milestones for our lead compound, onapristone. We were able to move onapristone forward very efficiently, culminating in the approval of our Phase I clinical trial design in France to evaluate onapristone in post-menopausal women with PR positive tumors, including breast, endometrial and others solid tumors, which has already begun enrolling patients in the first quarter of 2014. Additionally, we were able to complete a capital restructuring that resulted in the retirement of our convertible debentures and provided over $30 million in gross proceeds to Arno for the continued development of onapristone in the clinic."
...According to news reporting originating in Kenilworth, New Jersey, by NewsRx journalists, research stated, "Starting from indole-based hepatitis C virus (HCV) NS5B polymerase inhibitor lead compound 1, structure modifications were performed at multiple indole substituents to improve potency and pharmacokinetic (PK) properties."
Alex Zukiwski, MD, Chief Medical Officer of Arno Therapeutics, commented, "Tolerance to chemotherapy and various targeted therapies is known to be different in males undergoing androgen deprivation treatment. While the percentage of castration-resistant prostate cancer that is APR positive remains to be determined, the initial series of preclinical tumor specimens we examined has demonstrated evidence of APR, and we are looking forward to evaluating the safety and anticancer activity of onapristone in this patient population."
...indications with high unmet need: recurrent pregnancy loss and infertility ," said Jeffrey K Tong, Ph D , President and CEO of Nora Therapeutics. "We are further encouraged that enrollment in the THRIVE-IVF trial is ahead of schedule and we have already received significant investigator interest for the upcoming RESPONSE trial."

More Content

All (215) | News (173) | Reports (0) | Blogs (29) | Audio/Video (0) | Fact Sheets (1) | Press Releases (11)
sort by: Date | Relevance
Molecular Templates Presents Preclinical Data o... [Published 4 Traders - Apr 18 2014]
Arno Therapeutics annual net loss up [Published Individual.com - Apr 18 2014]
Data on Hepatitis C Virus Discussed by Research... [Published NewsRX - Apr 18 2014]
Arno Therapeutics enrolls first patient in Phas... [Published Individual.com - Apr 17 2014]
Novo A/S leads $18 mln Series B funding in Nora... [Published PE Hub Blog - Apr 17 2014]
Nora Therapeutics closes $18M Series B financin... [Published News-Medical.Net - Apr 17 2014]
Nora Therapeutics Announces $18 Million Series ... [Published PR Newswire - Apr 17 2014]
Nora Therapeutics Announces $18 Million Series ... [Published InvestorPoint.com - Apr 17 2014]
Oricula Therapeutics Secures Intellectual Prope... [Published HispanicBusiness.com - Apr 17 2014]
PanOptica raises $45m to finance clinical devel... [Published Big News Network - Apr 16 2014]
Medac Pharma gets FDA approval for trade name R... [Published Pharmaceutical Business Review - Apr 16 2014]
Drawbridge Pharmaceuticals Announces Successful... [Published BioSpace - Apr 16 2014]
PanOptica gets $45 million from series B financing [Published BioPortfolio - Apr 16 2014]
BerGenBio announces encouraging data from Phase... [Published Individual.com - Apr 16 2014]
Biopharma developer PanOptica scores $45m Seri... [Published AltAssets.net - Apr 16 2014]
PanOptica raises $45m to finance clinical devel... [Published PBR - News - Apr 16 2014]
U-M, MSU researchers find “off” switch for scle... [Published Health Canal - Apr 16 2014]
Medac Pharma, Inc. Secures FDA Approval of Trad... [Published Yahoo! Finance - Apr 15 2014]
Medac Pharma, Inc. Secures FDA Approval of Trad... [Published PR Newswire - Apr 15 2014]
PanOptica snags $45 mln Series B funds [Published PE Hub Blog - Apr 15 2014]
PanOptica Raises $45 Million to Finance Clinica... [Published Yahoo! Finance - Apr 15 2014]
Ziopharm: Attempting To Rise Again In A Crowded... [Published Seeking Alpha - Apr 15 2014]
Professor Raymond Schinazi Joins Board of reVir... [Published Yahoo! Finance - Apr 15 2014]
Albireo Lead Compound A4250 Shows Promise Again... [Published Bioresearch Online - Apr 14 2014]
PTC Therapeutics Looks Like A High-Risk Play On... [Published Citybizlist - Apr 12 2014]
PTC Therapeutics Looks Like A High-Risk Play On... [Published BioPortfolio - Apr 12 2014]
Advance in protecting mice from acid-mediated c... [Published Scientist Live - Apr 11 2014]
PTC Therapeutics Looks Like A High-Risk Play On... [Published Seeking Alpha - Apr 11 2014]
Albireo’s Lead Compound in Cholestatic Liver Di... [Published b3c Newswire - Apr 11 2014]
Albireo’s Lead Compound in Cholestatic Liver Di... [Published Ein News - Apr 11 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Novo A/S leads $18 mln Series B funding in Nora... [Published PE Hub Blog - Apr 17 2014]
Novo A/S has led an $18 million Series B funding in Nora Therapeutics , a biotechnology company focused on developing therapeutics to address needs in reproductive medicine. Other participants in the funding round included all Series A investors — ...
PanOptica raises $45m to finance clinical devel... [Published PBR - News - Apr 16 2014]
PanOptica has raised up to $45m in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically unique small-molecule selective inhibitor of VEGF (vascular endothelial growth factor) signaling being investigated ...
PanOptica snags $45 mln Series B funds [Published PE Hub Blog - Apr 15 2014]
PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences . Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical ...
WntResearch: WntResearch receives Notice of All... [Published Aktietorgets senaste nyheter - Apr 10 2014]
WntResearch AB today announces that it has received a Notice of Allowance from the Canadian patent office for its Foxy-5 patent application. The claims of the allowed patent application cover the company’s lead compound Foxy-5 and other related peptides, ...
Arno starts enrolling patients in Phase I/II tr... [Published PBR - News - Apr 08 2014]
Arno Therapeutics (ARNI), a US-based biopharmaceutical company, has initiated enrolling patients in a Phase I/II trial (NCT02049190) evaluating its lead compound 'onapristone' in men with advanced castration-resistant prostate cancer (CRPC) after failure ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Prosensa Announces 48-Week Data from a U.S. Pha... [Published GlobeNewswire: Advertising News - Mar 17 2014]
Cornerstone Pharmaceuticals Lead Compound CPI-6... [Published GlobeNewswire: Acquisitions News - Mar 12 2014]
Arno Therapeutics Granted Exclusive License for... [Published GlobeNewswire: Acquisitions News - Mar 04 2014]
AtheroNova Announces Preliminary Positive Phase... [Published GlobeNewswire: Advertising News - Feb 27 2014]
Arno Therapeutics Enrolls First Patient in a Ph... [Published GlobeNewswire: Advertising News - Jan 21 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.